Compile Data Set for Download or QSAR
maximum 50k data
Found 503 of ic50 data for polymerid = 938
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609083(US11702418, Example 1-18)
Affinity DataIC50:  0.730nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609068(US11702418, Example 1-8)
Affinity DataIC50:  1.60nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609081(US11702418, Example 1-16)
Affinity DataIC50:  1.60nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609087(US11702418, Example 1-22)
Affinity DataIC50:  1.70nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609086(US11702418, Example 1-21)
Affinity DataIC50:  1.80nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609067(US11702418, Example 1-7)
Affinity DataIC50:  2.10nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609064((R)—N-(1-(2-methyl-3-(trifluoromethyl)phenyl)...)
Affinity DataIC50:  2.10nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609063((R)—N-(1-(4-(2-((methylamino)methyl)phenyl)th...)
Affinity DataIC50:  2.30nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609071(US11702418, Example 1-10)
Affinity DataIC50:  2.30nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609375(US11702418, Example 3-3)
Affinity DataIC50:  2.30nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609069(US11702418, Example 1-9)
Affinity DataIC50:  2.30nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609088(US11702418, Example 1-23)
Affinity DataIC50:  2.40nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM50601065(CHEMBL5206295 | US11702418, Example 4-4)
Affinity DataIC50:  2.5nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609065(US11702418, Example 1-5)
Affinity DataIC50:  2.5nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609084(US11702418, Example 1-19)
Affinity DataIC50:  2.60nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609080(US11702418, Example 1-15)
Affinity DataIC50:  2.70nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM525146(US11168102, Example 32-31.)
Affinity DataIC50:  3.53nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609374(US11702418, Example 3-2)
Affinity DataIC50:  3.60nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609377(US11702418, Example 3-5)
Affinity DataIC50:  4nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609381(US11702418, Example 4-3)
Affinity DataIC50:  4.5nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM525147(US11168102, Example 32-32.)
Affinity DataIC50:  4.77nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609528((R)-4-methyl-7-(4-(1-methyl-1H-pyrazol-4-yl)pipera...)
Affinity DataIC50:  5nMAssay Description:Table 24: This Example illustrates that exemplary compounds of the present invention prevent KRas-mediated GTP nucleotide exchange mediated by SOS1 t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609372((R)—N-(1-(2-methyl-3-(trifluoromethyl)phenyl)...)
Affinity DataIC50:  5.20nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM525070(US11168102, Example 18.)
Affinity DataIC50:  5.79nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609384(US11702418, Example 5-2)
Affinity DataIC50:  5.90nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609082(US11702418, Example 1-17)
Affinity DataIC50:  6.20nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609380(US11702418, Example 4-2)
Affinity DataIC50:  6.30nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM50601091(CHEMBL5171096 | US11702418, Example 4-1)
Affinity DataIC50:  6.5nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM525148(US11168102, Example 32-51.)
Affinity DataIC50:  6.77nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609066(US11702418, Example 1-6)
Affinity DataIC50:  6.80nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609069(US11702418, Example 1-9)
Affinity DataIC50:  7nMAssay Description:Table 23: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and inhibit the SOS1-mediated nucleotide exchange o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609064((R)—N-(1-(2-methyl-3-(trifluoromethyl)phenyl)...)
Affinity DataIC50:  7nMAssay Description:Table 23: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and inhibit the SOS1-mediated nucleotide exchange o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609383((R)—N-(1-(5-(2-((dimethylamino)methyl)phenyl)...)
Affinity DataIC50:  7.20nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM525132(US11168102, Example 57.)
Affinity DataIC50:  7.65nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM525055(US11168102, Example 8-4.)
Affinity DataIC50:  7.66nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609653(US11702418, Example 15-2)
Affinity DataIC50:  8nMAssay Description:Table 24: This Example illustrates that exemplary compounds of the present invention prevent KRas-mediated GTP nucleotide exchange mediated by SOS1 t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609681(US11702418, Example 20-2)
Affinity DataIC50:  8nMAssay Description:Table 24: This Example illustrates that exemplary compounds of the present invention prevent KRas-mediated GTP nucleotide exchange mediated by SOS1 t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609067(US11702418, Example 1-7)
Affinity DataIC50:  8nMAssay Description:Table 23: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and inhibit the SOS1-mediated nucleotide exchange o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609068(US11702418, Example 1-8)
Affinity DataIC50:  8nMAssay Description:Table 23: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and inhibit the SOS1-mediated nucleotide exchange o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM525128(US11168102, Example 32-19.)
Affinity DataIC50:  8.82nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609065(US11702418, Example 1-5)
Affinity DataIC50:  9nMAssay Description:Table 23: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and inhibit the SOS1-mediated nucleotide exchange o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609529(7-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-4-methyl-...)
Affinity DataIC50:  9nMAssay Description:Table 24: This Example illustrates that exemplary compounds of the present invention prevent KRas-mediated GTP nucleotide exchange mediated by SOS1 t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM524861(US11168102, Example 1.)
Affinity DataIC50:  9nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609071(US11702418, Example 1-10)
Affinity DataIC50:  9nMAssay Description:Table 23: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and inhibit the SOS1-mediated nucleotide exchange o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609253(US11702418, Example 2-3)
Affinity DataIC50:  10nMAssay Description:Table 21: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609415(US11702418, Example 6-5)
Affinity DataIC50:  10nMAssay Description:Table 24: This Example illustrates that exemplary compounds of the present invention prevent KRas-mediated GTP nucleotide exchange mediated by SOS1 t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609534(US11702418, Example 12-9)
Affinity DataIC50:  10nMAssay Description:Table 24: This Example illustrates that exemplary compounds of the present invention prevent KRas-mediated GTP nucleotide exchange mediated by SOS1 t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609522((R)-(4-(1-methyl-4-((1-(2-methyl-3-(trifluoromethy...)
Affinity DataIC50:  10nMAssay Description:Table 24: This Example illustrates that exemplary compounds of the present invention prevent KRas-mediated GTP nucleotide exchange mediated by SOS1 t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM525049(US11168102, Example 4.)
Affinity DataIC50:  10.8nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSon of sevenless homolog 1 [564-1049]()
Mirati Therapeutics

US Patent
LigandPNGBDBM609680(1-(3-((R)-1-((7-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]...)
Affinity DataIC50:  11nMAssay Description:Table 24: This Example illustrates that exemplary compounds of the present invention prevent KRas-mediated GTP nucleotide exchange mediated by SOS1 t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 503 total ) | Next | Last >>
Jump to: